HNGEHinge Health, Inc.
Is the price fair?
Growth expectations in line with delivery. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~6% a year FCF growth. Moderate growth expectations are priced in.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What HNGE's price assumes
Hinge Health, Inc. has no trailing P/E on file, so the price is measured against sales instead: 8.71× revenue.
Price / sales · no trailing P/E on file: measured against sales instead
- Free cash flow yield
- 5.0%
Free cash flow yield · Health Information Services median 6.3%
- Growth the price implies
- +5.7%
Growth the price implies · What free cash flow would have to do every year for a decade to justify today's price, discounted at 9.0%.
- Price / book
- 18.2
Price / book · as of 2026-Q2
Details›
- Price / bookas of 2026-Q2
- 18.2
- Free cash flow, trailing twelve months
- $290M
- Market capitalisation
- $5.81B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Health Information Services
The closest names by size in the same industry